Newsfile Corp
29 Jul 2026, 11:45 UTC · 6h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA concluded that deramiocel's data did not provide substantial evidence of effectiveness and noted the application relied on only a single pivotal trial. — This directly threatens the approval of the company's primary cell therapy candidate, which is a fundamental driver of its valuation.
-0.90Reports indicate Capricor made multiple changes to its statistical analysis plan after the study was completed, raising concerns about data manipulation to generate positive outcomes. — Allegations of 'p-hacking' or post-hoc analysis changes severely damage scientific credibility and increase the likelihood of regulatory rejection.
-0.70Law firm Block & Leviton is investigating Capricor Therapeutics for potential securities law violations related to its regulatory representations. — Legal investigations and potential class-action lawsuits create additional financial liability and governance risk for the company.
-0.40Continue reading
6 related stories
Top 2 movers · tap to explore
Which stocks this story touches
The company is under investigation for securities law violations following a 60% stock price drop and negative FDA briefing documents.
The article mentions that shares have dropped again and investors are encouraged to contact a law firm for potential recovery.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
6h ago
